Recently, cyclin-E was reported to be the most prominent prognostic factor for breast cancer outcome described so far, even surpassing axillary nodal involvement. Earlier studies on the prognostic value of cyclin-E in breast cancer, however, yielded heterogeneous results. Therefore, we set out to confirm and extend these results by quantitative Taqman RT-PCR of cyclin-E levels in 277 resectable breast cancers. Cyclin-E levels were not associated with relapse-free survival (RFS) or overall survival (OS) in the total cohort of patients, or in the subset of patients without involved lymph nodes that were not treated with adjuvant systemic therapy. Besides several classical clinicopathological factors, the interaction between cyclin-E and adjuvant endocrine therapy (P ¼ 0.01, HR ¼ 3.04, 95% CI: 1.30-7.09) was found to contribute significantly in multivariate analyses. Cyclin-E levels were associated with poor RFS specifically in patients treated with adjuvant endocrine therapy (n ¼ 108, P ¼ 0.001, HR ¼ 4.01, 95% CI: 1.76-9.12), independent of estrogen receptor status. In conclusion, cyclin-E is not a pure prognostic factor in breast cancer, but rather a predictor of failure of endocrine therapy. Differences in literature on the presumed prognostic value of cyclin-E may be due to differences in treatment. Assessment of cyclin-E levels can aid in improving adjuvant treatment selection.
Introduction
Cyclin-E, the regulatory subunit of cyclin-dependent kinase 2 (Cdk2), is an important regulator of S phase entry in the cell cycle. In normal cells, cyclin-E accumulates at the G 1 /S phase boundary and is degraded as cells progress through the S phase (Dulic et al., 1992; Koff et al., 1992) . Cyclin-E is deregulated relative to the cell cycle in many tumors (Keyomarsi and Herliczek, 1997) , including breast tumors (Keyomarsi and Pardee, 1993; Keyomarsi et al., 1995) . Recently, cyclin-E was described as a powerful predictor of poor outcome in breast cancer (Keyomarsi et al., 2002) . In fact, the prognostic power of cyclin-E surpassed that of nodal involvement, which would make it the most prominent prognostic factor for breast cancer outcome described so far.
Research on breast cancer of the last decades has yielded numerous potential prognostic factors. However, the estrogen (ER) and/or progesterone receptor (PgR) status are the only biological factors, besides clinicopathological criteria like axillary lymph node status, tumor size, grade and age, that are regularly used for clinical decision making. The reason why so few, if any, potential prognostic biological factors are incorporated into clinical practice might be the generally heterogeneous results reported on such factors. This is often attributed to differences in assessment or quantification of the factor, differences in the patient population, availability and nature of tumor material, final statistical analysis, etc. Similarly, cyclin-E has been the subject of research for breast cancer prognosis before. Some studies (Nielsen et al., 1996; Porter et al., 1997) concur at least in part with that of Keyomarsi et al. (2002) , whereas others found that cyclin-E is either not an independent factor, losing its prognostic value in multivariate analysis (Donnellan et al., 2001; Ku¨hling et al., 2003) , or is of limited value, only predicting site of relapse (Kim et al., 2001) .
Considering the potentially profound clinical importance of a new factor with strong prognostic characteristics as recently reported for cyclin-E (Keyomarsi et al., 2002) , we wanted to confirm and extend these data on cyclin-E in human breast cancer by a retrospective analysis of cyclin-E mRNA levels in 277 human breast cancer tissues from patients with extensive clinical follow-up data, including adjuvant treatment modality, local and regional tumor control, relapse free-(RFS) and overall survival (OS).
Results
In all 277 breast tumor tissue samples, cyclin-E mRNA levels could be quantified. Levels ranged from 1 Â 10 to 2.3 Â 10 À2 cyclin-E/b-actin. The median level was 9.1 Â 10
À4
, with an interquartile range of 1.3 Â 10 À3 . A basically normal distribution was found after log transformation of these values (Figure 1 ).
The median cyclin-E levels in the different subcategories of patients are shown in Table 1 . Levels differed between histological grades (Po0.001), but no significant trend could be ascertained between histological grade and cyclin-E levels (P ¼ 0.456). Similarly, cyclin-E levels were not related to tumor size in the test for trend (P ¼ 0.876). Of note, cyclin-E levels were significantly higher in steroid hormone receptor-negative cases (Po0.001 for both ER and PgR). In the ER-positive tumors, however, no correlation between the amounts of ER and cyclin-E could be found (Rs ¼ 0.204, P ¼ 0.463, data not shown).
The prognostic value of clinicopathological factors, treatment modality and cyclin-E for RFS was assessed in univariate Cox regression analysis (Table 2) . Age was a significant prognostic factor, with increasing age denoting a more favorable prognosis (P ¼ 0.005). Tumor size was of borderline significance (P ¼ 0.057), and histological grade did also predict a poor RFS with increasing grade (P ¼ 0.030). The most pronounced prognostic factor in univariate analysis was the number of involved nodes (Po0.001). Compared to patients without nodal involvement, the presence of 1-3 or more than three involved lymph nodes indicated a 1.76-(95% CI: 1.03-2.99) or 3.97-(95% CI: 2.34-6.71) fold higher hazard rate (HR). Remarkably, cyclin-E levels were not associated with RFS (P ¼ 0.246, HR ¼ 1.33, 95% CI: 0.82-2.13) or OS (P ¼ 0.544, HR ¼ 1.21, 95% CI: 0.67-2.22, data not shown) in univariate analysis. Thus, we were not able to confirm the previously reported strong association of cyclin-E levels with prognosis in breast cancer. Therefore, we next assessed the prognostic value of cyclin-E levels in the nodenegative patients who did not receive adjuvant treatment to be able to detect a relation between cyclin-E and the natural course of the disease, that is a pure prognostic value. In these 104 patients, cyclin-E levels also did not contribute to RFS (P ¼ 0.274, HR ¼ 0.56, 95% CI: 0.20-1.59) or OS (P ¼ 0.916, HR ¼ 0.97, 95% CI: 0.28-3.39). Subsequently, we extended our observations by exploring treatment interactions as a possible explanation for this apparent discrepancy with earlier studies. In these multivariate analyses concerning adjuvant treatment interactions, only RFS was used as end-point parameter, and not OS, as after recurrence patients are treated with additional therapy for advanced disease, obscuring pure adjuvant treatment effects. Subsequently, multivariate Cox regression analyses were conducted in two blocks. Firstly, a model including all established clinicopathological factors was fitted with backward stepwise selection of significant factors based on their likelihood ratio. In a second block, the contributions of cyclin-E (as a continuous, log-transformed variable), treatment and their interactions were investigated with the same selection procedure ( Table 3 ). Factors that contributed significantly to prognosis in multivariate analysis for RFS were age (P ¼ 0.001), tumor size (P ¼ 0.035), number of involved nodes (Po0.001), adjuvant chemotherapy (P ¼ 0.035) and the interaction between adjuvant endocrine therapy and cyclin-E (P ¼ 0.010). The latter factor had a HR of 3.04 (95% CI: 1.30-7.09). This indicates that patients with high cyclin-E levels react poorly to endocrine therapy. No other treatment interactions were found. Similar associations were found when the factors in the first block were entered (thus no selection was made for these factors), and when either a forward or a backward stepwise selection was performed in the second block (data not shown).
The cyclin-E by endocrine treatment interaction was subsequently characterized by exploratory subset analyses. In univariate Cox regression analysis, cyclin-E levels were associated with poor RFS in patients treated with adjuvant endocrine therapy only (n ¼ 108, P ¼ 0.001, HR ¼ 4.01, 95% CI: 1.76-9.12, see Table 4 ).
For visualization purposes in a Kaplan-Meier curve, the optimal cutoff value for predicting endocrine therapy failure by cyclin-E, significantly associated with c Multivariate analyses were conducted in two blocks. Firstly, a model including all established clinicopathological factors was fitted. In a second block, the contributions of cyclin-E (as a continuous, log-transformed variable), treatment, and interactions were investigated.
d Cutoff point used for ER and PgR, 10 fmol/mg protein RFS as a continuous variable, was obtained by multiple testing (Figure 2a ). At the optimal cutoff of 1.5 Â 10 À3 , the 24 patients with the highest cyclin-E levels who were treated with endocrine therapy had a mean RFS time of 54 months, whereas the 84 patients whose tumors exhibited low levels of cyclin-E had a mean RFS time of 73 months (Po0.001, log-rank testing).
To investigate whether cyclin-E could add to the established predictive value of steroid hormone receptor status for the success of endocrine therapy, a multivariate model was fitted for RFS in endocrine-treated patients, including ER and PgR. Only ER was found to be of prognostic value in endocrine-treated patients (n ¼ 108) in this model (P ¼ 0.010, HR 0.40, 95% CI: 0.20-0.80). Subsequently, the effect of addition of cyclin-E as a continuous variable to the model was assessed. This final model included both ER (P ¼ 0.052, HR 0.47, 95% CI: 0.22-1.00) and cyclin-E (P ¼ 0.045, HR ¼ 2.57, 95% CI: 1.00-6.46). This additive predictive value of both ER and cyclin-E in endocrine-treated patients is shown in Figure 2b , where patients could be significantly (Po0.001) stratified by both ER and cyclin-E.
Discussion
Here we show, by a retrospective analysis of cyclin-E mRNA levels in archival tissues from 277 patients with resectable breast cancer, that cyclin-E is not a true, pure prognostic factor, but rather a predictive factor. Steroid hormone receptor negative tumors exhibited the highest cyclin-E levels, and high levels of cyclin-E were associated with failure after adjuvant endocrine treatment. This was not attributable to a lower relative ER content in cyclin-E overexpressing ER-positive tumors. The predictive value of cyclin-E for endocrine therapy failure added to the predictive information already obtained from ER status. Therefore, cyclin-E can help to improve the adjuvant treatment of patients with invasive breast cancer.
We were not able to confirm the recent report on cyclin-E as a powerful predictor of poor outcome in an unselected cohort of breast cancer patients (Keyomarsi et al., 2002) . To be able to distinguish between a true, pure, prognostic value of cyclin-E and possible treatment interactions, we have assessed the prognostic value of cyclin-E levels in the node-negative patients who did not receive adjuvant treatment. In these 104 patients, cyclin-E levels did not contribute to RFS, nor to OS. Therefore, we extended our observations by exploring treatment interactions as a possible explanation for the apparent discrepancy with earlier studies. For this aim, only RFS can be used as an end point parameter, and not OS, as after recurrence patients are treated with additional therapy for advanced disease, obscuring pure adjuvant treatment effects. These analyses demonstrated a strong treatment interaction between cyclin-E and endocrine therapy. These results suggest that the heterogeneous results on the prognostic value of cyclin-E (Nielsen et al., 1996; Porter et al., 1997; Donnellan et al., 2001; Kim et al., 2001; Ku¨hling et al., 2003) might very well be attributable to differences in the adjuvant treatment of these patients. In our group of retrospectively collected patients, 108/277 (39%) To ascertain radiotherapy effects, patients who received adjuvant treatment were excluded for this subset analysis Figure 2 Patients treated with endocrine therapy only, n ¼ 108: (a) dichotomized by cyclin-E levels, Po0.001 (log rank); (b) dichotomized by both ER (cutoff 10 fmol/mg protein) and cyclin-E levels (cutoff 1.5 Â 10 À3 ), Po0.001 (log rank)
Cyclin-E is a predicts adjuvant endocrine therapy failure PN Span et al patients received endocrine treatment, whereas in other studies only 10 ( Kim et al., 2001 ) to 18% (Ku¨hling et al., 2003) are described to have received endocrine adjuvant treatment. The majority of our patients were treated with tamoxifen due to the consensus at the time of primary surgery of these patients. This also included the use of tamoxifen in a significant number of patients with ER-and PgR-negative tumors, which is no longer common practice. Many of the other reports on cyclin-E have not indicated what, if any, adjuvant treatment was given to the patients. Thus, the prognostic value of new factors can be obscured when putative predictive effects are not taken into account. To establish this predictive value of cyclin-E, only prospective studies with randomization to endocrine treatment could yield irrefutable results. The involvement of cyclin-E with breast cancer prognosis has been attributed to its association with cell cycle regulation and cellular proliferation (Ku¨hling et al., 2003) , chromosomal instability (Spruck et al., 1999) , or (anti) estrogen-independent growth (Bindels et al., 2002; Dhillon and Mudryj, 2002) . Our results strongly indicate that the latter mechanism is of physiological importance in breast cancer. Thus, as reported in MCF7 cells (Dhillon and Mudryj, 2002) , overexpression of cyclin E could counteract tamoxifenmediated growth arrest in human breast cancer patients. If the independent association of cyclin-E with endocrine therapy success prediction holds true in additional confirmatory studies, cyclin-E could be of significant value for selecting patients eligible for endocrine treatment in addition to steroid hormone receptor status. Keyomarsi et al. (2002) indicated that their results might differ from others due to the fact that they measured both total and low-molecular-weight forms of cyclin-E, using an antibody directed against the Cterminal of the protein, by Western blotting. These authors suggested that other studies might miss the hyperactive, low-molecular-weight forms of cyclin-E generated by proteolytic cleavage of the full-length form (Porter et al., 2001) . To overcome these analytical problems often associated with protein-directed assay techniques because of post-transcription and/or posttranslation modifications, we opted for a previously described quantitative RT-PCR to determine mRNA levels of cyclin-E (Mu¨ller-Tidow et al., 2001 ). This assay was earlier shown to yield values closely associated to total cyclin-E protein levels (Mu¨ller-Tidow et al., 2001) . On the other hand, diminished proteolysis could also be involved in deregulated cyclin-E levels, as described in a breast cancer cell line with high cyclin-E (Strohmaier et al., 2001) . Using this method, we confirmed the previously described negative correlation of cyclin-E levels with ER in breast cancer determined by Western blotting, immunohistochemistry, or quantitative RT-PCR (Nielsen et al., 1996 (Nielsen et al., , 1997 Donnellan et al., 2001; Payton et al., 2002; Ku¨hling et al., 2003) . This association of mRNA with protein data concurs with the early observation that gene amplification and increased transcription of cyclin-E is implicated in its overexpression in breast cancer (Keyomarsi and Pardee, 1993) . Similar to the earlier studies on cyclin-E protein and breast cancer prognosis, confirmation of our results in independent studies is essential.
The optimal cutoff value we derived for the KaplanMeier curve indicated that 24/108 (22%) of the endocrine treated, and 78/277 (28%) of the total group were to be denoted as having high cyclin-E levels. Deriving an optimal cutoff value, however, is associated with a considerable type I error rate (Altman et al., 1994) . Therefore, our Cox regression analyses were performed with cyclin-E as a continuous variable. The cutoff value we used for dichotomization in the KaplanMeier analysis led to similar groups as in earlier reports: Nielsen et al. (1996) reported a poor prognosis for 27/ 100 (27%) and Keyomarsi (Keyomarsi et al., 2002) for 127/395 (32%) of patients with high cyclin-E protein levels as assessed by Western blotting. These cutoff levels were determined either subjectively (Nielsen et al., 1996) , or at levels higher than found in normal breast tissue (Keyomarsi et al., 2002) . Remarkably, although similar methods were used in both these papers (Nielsen et al., 1996; Keyomarsi et al., 2002) , Nielsen et al. (1996) reported very low to undetectable levels in normal breast tissue. On the other hand, quantitative RT-PCR also indicated that 23% of tumors overexpress cyclin-E compared to normal tissue (Payton et al., 2002) . These results also confirm the strong relation between mRNA and protein cyclin-E levels in tumor tissue. Notwithstanding the consistent results of the quantitative RT-PCR with other (protein) techniques, we could not establish a prognostic value of cyclin-E with RFS or OS in the total group of unselected breast cancer patients.
In conclusion, cyclin-E is not a prognostic factor for RFS in a large group of resectable, invasive breast cancer patients. We showed that cyclin-E is, in fact, a predictor of failure of endocrine therapy in addition to ER status. Differences in literature on the presumed prognostic value of cyclin-E may thus be due to differences in patient adjuvant treatment. Assessment of cyclin-E levels can aid in the improvement of patient selection for endocrine treatment.
Patients and methods

Tissue selection
Tumor tissue was obtained from patients with unilateral breast cancer after surgical resection of the primary tumor. Patients who had received neoadjuvant treatment, a previous diagnosis of cancer, or with recurrent disease within 1 month after surgery, were excluded. Furthermore, patients with carcinoma in situ or with distant metastases at the time of diagnosis were excluded. After surgery, performed between November 1987 and December 1997 in five different hospitals of the Comprehensive Cancer Center East in the Netherlands, a representative part of tumor was selected by a pathologist, frozen in liquid nitrogen and sent to our department for routine determination of ER and PgR status by ligand-binding assay. After routine tissue processing by pulverizing using a microdismembrator (Braun, Melsungen, Germany), the remaining frozen tissue or tissue powder was kept in liquid nitrogen. For the current study, samples were selected based on the availability of tissue in the tumor bank. The local ethical committee approved the current study.
Patients
In total, 277 patients were included. The median age was 60 years (range 31-88 years). Patients underwent modified radical mastectomy (n ¼ 203) or a breast-conserving lumpectomy (n ¼ 74). Postoperative radiotherapy was given in 201 patients, to the breast after an incomplete resection or after breast-conserving treatment, or to the axillary or supraclavicular region, depending on the degree of nodal involvement. Lymph node involvement was found in 146 patients. Subsequent systemic adjuvant therapy was given based on established clinicopathological criteria at that time. In the absence of involved axillary lymph nodes, patients usually did not receive adjuvant treatment. When involved axillary lymph nodes were detected, premenopausal patients received chemotherapy. In the case of an ER-and/or PgR-positive primary tumor, additional endocrine therapy was given to these patients. Postmenopausal patients with involved axillary lymph nodes and an ERand/or PgR-positive tumor received adjuvant endocrine therapy. If the primary tumor of these patients was hormone receptor negative, no adjuvant therapy was given, although in some cases endocrine therapy was opted for. Patients treated with endocrine therapy (n ¼ 108) received tamoxifen for at least 2 years. In total, 48 patients received adjuvant chemotherapy. Adjuvant chemotherapy consisted of six cycles of the classic cyclophosphamide/methotrexate/5-fluorouracil (CMF) schedule, or in some patients five or six cycles of 5-fluorouracil, epirubicine/adriamycin and cyclophosphamide (FEC/FAC). Of the patients receiving adjuvant therapy, 18 patients received both endocrine therapy and chemotherapy, and are reported in both treatment arms. In the absence of complaints or suspicion of relapse, patients were routinely seen (history, physical examination, routine laboratory investigations) once every 3 months during the first 2 years, once every 6 months for 5 years and once a year thereafter. Once a year, X-ray mammography was made. The median follow-up time was 75 months (range 2-169 months). During follow-up, 102 patients had a recurrence (22 locoregional, 78 distant metastases, two both) and 81 patients died (61 confirmed breast cancer-related, two by other malignancy, 18 other or unknown). Contralateral breast cancer or second malignancies were not considered as recurrent disease.
Tissue processing
Total RNA was isolated from approximately 20 mg of tissue powder using the RNeasy mini kit (Qiagen, Hilden, Germany) with on-column DNase-I treatment.
Quality of the RNA was checked by examining ribosomal RNA bands after agarose gel electrophoresis, and by amplifying b-actin as a control (see below). RNA concentrations were determined from the spectrophotometric absorption at 260 nm using the Genequant (Amersham, Eindhoven, The Netherlands). No association of RNA degradation or concentration with length of storage time was found.
RT-PCR
Purified total RNA (1.0 mg) was denatured for 10 min at 701C, and immediately cooled on ice. Reverse transcription was performed using the Reverse Transcription System (Promega Benelux BV, Leiden, the Netherlands) according to the manufacturer's protocol. After annealing of random hexamers for 10 min at 201C, cDNA synthesis was performed for 60 min at 421C, followed by an enzyme inactivation step for 5 min at 951C. Quantitative PCR for cyclin-E was performed as reported earlier (Mu¨ller-Tidow et al., 2001) . The cyclin-E (primer positions are shown for accession number NM001238) forward primer was 5 0 -CTC CAG GAA GAG GAA GGC AA-3 0 (positions 264-283), and the reversed primer was 5 0 -TCG ATT TTG GCC ATT TCT TCA-3 0 (positions 312-332). The TET-labeled Taqman probe was 5 0 -TET-CGT GAC CGT TTT TTT GCA GGA TCC-TAMRA-3 0 (positions 285-308). This format will amplify both transcript variants (accession numbers NM001238 and NM057182) with a PCR product length of 68 nucleotides. Quantifications were performed using the cell line MDA-MB175 as a calibrator. Amplifications were performed using Universal Master Mix (PE Applied Biosystems, Nieuwerkerk a/d lJssel, The Netherlands) in a volume of 25 ml. All samples were normalized for b-actin expression using predeveloped assay reagents (PE Applied Biosystems). Only samples with strong amplification of b-actin (C t o25) were included in the final analyses. In a preliminary study, the concurrent associations of 13 different housekeeping genes were assessed in 16 different breast cancer samples. b-Actin was found to be one of several genes that showed constant expression levels, and was thus considered well suited to be used as housekeeping gene in the present study (unpublished results). Amplifications, with denaturation at 951C for 10 min, and 40 cycles of 15 s at 951C (melting) and 60 s at 601C (annealing and elongation), were performed on an ABI Prism 7700 Sequence detection system (PE Applied Biosystems).
Statistical analyses
Statistical analyses were carried out using SPSS 10.0.5 software (SPSS Benelux BV, Gorinchem, The Netherlands). Levels are shown as median with interquartile range, or after log transformation to obtain a normal distribution as tested by Kolmogorov-Smirnov testing. Differences in levels of cyclin-E expression in samples from patients categorized by clinicopathological characteristics, used as grouping variables, were assessed with either nonparametric Mann-Whitney U or Kruskall-Wallis testing, with subsequent test for trend when significant. RFS time (defined as the time from surgery until diagnosis of recurrent disease) and OS time (defined as the time between date of surgery and death by any cause) were used as follow-up end points. The Cox proportional hazards model (Cox, 1972) was used to assess the prognostic value of cyclin-E expression (as a continuous variable after log transformation) and other clinicopathological factors in both univariate and multivariate analyses. In multivariate analysis, only RFS was used as end-point parameter, and not OS, as after recurrence patients are treated with additional therapy for advanced disease, obscuring pure adjuvant treatment effects. Multivariate Cox regression analyses were conducted in two blocks. Firstly, a model including all established clinicopathological factors, irrespective of statistical significance in univariate analysis as has been recommended by Altman and Lyman (1998) for exploratory studies into new prognostic factors, was fitted with backward stepwise selection of significant factors based on their likelihood ratio. In a second block, the contributions of cyclin-E (as a continuous, log-transformed variable), treatment (radiotherapy, endocrine therapy or chemotherapy) and their interactions (by inclusion of product variables as described (Altman and Lyman, 1998; Harbeck et al., 2002; Foekens et al., 2003) ) were investigated with the same selection procedure. Survival curves were generated using the method of Kaplan and Meier (1958) . The patient group was dichotomized by the optimal cutoff value obtained by multiple univariate Cox regression analysis (minimal P-value approach (Altman et al., 1994) ). Equality of survival distributions was tested using log-rank testing. Two-sided P-values below 0.05 were considered to be statistically significant. Cases with more than 84 months of follow-up were censored at 84 months, because of the rapidly declining number of patients thereafter. After a certain period of observation, patients are frequently redirected to their general practitioner for checkups and mammography and cease to belong to the outpatients collective of our breast cancer clinic.
